Frédéric Joliot Institute for Life Sciences - Sur le même thème

Biotherapies: the risk of immunogenicity associated with nanobodies

Tue, 31 Mar 2026 10:00:00 GMT

Nanobodies, promising biotherapeutic agents, may trigger undesirable immune reactions. A team from SIMoS demonstrates, using a sensitive assay on human T lymphocytes, that this risk exists for certain nanobodies and can be reduced through sequence humanization. These findings highlight the importance of assessing immunogenicity alongside therapeutic efficacy.

Toward CAR-macrophage-based cellular immunotherapy for treating certain solid tumors?

Mon, 09 Mar 2026 11:00:00 GMT

Researchers from our DMTS department have published a study providing the first proof of concept for a CAR-macrophage therapy targeting the endothelin B receptor, which is overexpressed in melanoma cells.

Multiple Sclerosis: Assessing AI Tools for Prognostic Support

Mon, 02 Feb 2026 11:00:00 GMT

Researchers from the BioMaps laboratory (SHFJ) demonstrate the value of artificial intelligence software in interpreting MRI data for monitoring individuals with multiple sclerosis. However, validation by clinical radiologists remains essential to ensure the accuracy of the interpretation.

Opening the BBB to Deliver Drugs to the Brain: Removing Noise Signals to Optimize Focused Ultrasound Pressure Control Protocol

Wed, 14 Jan 2026 11:00:00 GMT

Teams from BioMaps (SHFJ) and BAOBAB (NeuroSpin), along with CEA-Jacob, are optimizing their strategy for opening the blood-brain barrier (BBB) using focused ultrasound (FUS) to deliver drugs to the brain. Their innovation: an algorithm that identifies and 'eclipses' extracranial cavitation induced by thick temporal muscles—particularly in large male primates—which otherwise masks the signal of interest.

PET Imaging Reveals the Effects of Ketamine on Synaptic Plasticity in a Model of Depression

Mon, 22 Dec 2025 11:00:00 GMT

Researchers from BioMaps (SHFJ) and MOODS have validated an innovative molecular neuroimaging approach that allows non-invasive monitoring of ketamine’s effects on synaptic density in a preclinical model of depression.

Using Light to Switch Off the MRI Signal of Micellar Probes for Diagnostic Purposes

Fri, 05 Dec 2025 11:00:00 GMT

Researchers at the SCBM and BAOBAB have developed a new version of their nanometric micellar vector designed for fluorine-19 magnetic resonance tumor imaging. This version is intended to enhance MRI contrast by switching off the signal on demand in certain areas, while preserving it in pathological regions to be imaged.

Proof of concept for the passage of trastuzumab formulated in nanoparticles through an in vitro-reconstituted nasal epithelium.

Wed, 12 Nov 2025 11:00:00 GMT

Researchers from SPI (DMTS) developed a formulation of PLGA nanoparticles loaded with the anticancer trastuzumab (NP-TZB) and measured their ability to cross a cellular model of the nasal epithelial barrier. This first validated step supports a potential nose-to-brain (N2B) delivery route.

Cyanine 5-huwentoxin-IV : a new imaging agent for non-small cell lung cancer ?

Mon, 10 Nov 2025 11:00:00 GMT

A team from SIMoS (DMTS) has demonstrated the ability of a peptide derived from a spider venom toxin to detect overexpressed sodium channels in a metastatic non-small cell lung cancer (NSCLC) cell line.

PET imaging of OATP transporter-mediated drug elimination: impacts of sex and age

Wed, 15 Oct 2025 10:00:00 GMT

Researchers from BioMaps (SHFJ) investigated the hepatic activity of organic anion-transporting polypeptides (OATPs), key players in the elimination of certain drugs, using a PET imaging approach with 11C-glyburide, which revealed differences in tracer pharmacokinetics between men and women.

Développement de radioligands pour l’imagerie TEP de la neuroinflammation

Fri, 03 Oct 2025 10:00:00 GMT

Des chercheurs du SHFJ, en collaboration avec le CEA-Jacob, le CRN à Lyon et le PharmaCenter à Bonn ont imaginé, synthétisé et caractérisé deux radiotraceurs TEP ciblant P2Y12, une protéine impliquée dans l’activation de la microglie durant la neuroinflammation.

Llama antibodies: new therapeutic avenues against schizophrenia

Wed, 10 Sep 2025 10:00:00 GMT

Researchers from SIMoS (DMTS) contributed to the characterization of a nanobody (VHH) designed by scientists at the Institut de Génomique Fonctionnelle in Montpellier. They performed tritium labeling and biodistribution tracking of this VHH, which can specifically activate a glutamate receptor involved in schizophrenia. This work was published in Nature.

Unprecedented method for high-yield production of monoclonal antibodies through targeted cell fusion

Fri, 05 Sep 2025 10:00:00 GMT

Researchers at SPI (DMTS) have developed a high-yield strategy for producing monoclonal antibodies by preselecting the antibody-producing cells most likely to form viable hybridomas. This represents a step towards a wider use of this technology which should help to further reduce the number of animals to be immunised.

Ultrasound to counteract the cerebral effects of exposure to a neurotoxic agent

Thu, 28 Aug 2025 10:00:00 GMT

Researchers from BioMaps (SHFJ), NeuroSpin, and the french IRBA developed an innovative approach using focused ultrasound to improve brain delivery of an antidote, oxime, following exposure to an organophosphorus neurotoxic agent in a murine model.

Cancer : transformer la mertansine en prodrogue pour une chimiothérapie ciblée et moins toxique grâce à une approche théranostique.

Tue, 01 Jul 2025 10:00:00 GMT

Une équipe du laboratoire BioMaps, en collaboration avec l’Institut Galien Paris-Saclay a mis au point une stratégie innovante associant une prodrogue polymère et l'imagerie par tomographie par émission de positons (TEP) pour améliorer l'efficacité de la mertansine, un agent antitumoral puissant mais toxique.

A promising drug candidate for the treatment of neonatal hypoxic-ischemic encephalopathy

Thu, 26 Jun 2025 10:00:00 GMT

Researchers from the SPI (DMTS) and the Women & Infants Hospital in Providence have laid the molecular basis for the neuroprotection of a purine derivative in a preclinical model of neonatal hypoxic-ischemic encephalopathy (HIE). The promising results support the development of this drug candidate to treat HIE in neonates.

A new toxin derived from snake venom to treat kidney diseases

Thu, 20 Mar 2025 11:00:00 GMT

Researchers at SIMoS, SPI (DMTS) and BioMaps (SHFJ) report the development of a new molecule, MQ232, derived from mambaquaretin. As a specific antagonist of the vasopressin V2 receptor, MQ232 is a promising drug candidate for the treatment of renal pathologies.

Deutération : le déblocage d'un verrou méthodologique au potentiel industriel

Thu, 13 Feb 2025 11:00:00 GMT

Une étude menée par le SCBM présente une approche innovante permettant de relever les défis actuels des méthodes d'échange isotopique hydrogène - deutérium en offrant un processus efficace, reproductible et évolutif. Ave à la clef, de possibles développements industriels dans les domaines des médicaments et des technologies OLED.

Un test bandelette pour détecter les infections à Candida auris

Mon, 20 Jan 2025 11:00:00 GMT

Des chercheurs du LERI (SPI/DMTS), en collaboration avec NG Biotech, ont développé un test-bandelette de détection de Candida auris, un champignon à l’origine d’infections nosocomiales de plus en plus fréquentes. Leurs premiers résultats sur des souches isolées indiquent d’excellentes performances du dispositif.

Immunological profiling of cancer : when click-chemistry meets mass spectrometry

Mon, 13 Jan 2025 11:00:00 GMT

Researchers at DMTS and SHFJ have carried out a multiplexed analysis of tumor cells and tissues, based on the use of cleavable therapeutic antibodies carrying mass tags, for the identification and quantification of cancer biomarkers. A proof-of-concept demonstrating the high potential of this tumor immunoprofiling approach

SplineBeam : un algorithme réaliste et rapide pour prédire les champs de pression des ultrasons.

Thu, 24 Oct 2024 10:00:00 GMT

Les applications thérapeutiques des ultrasons sont nombreuses, notamment en neurologie. Prédire en temps réel le champ de pression acoustique à appliquer est indispensable. C’est ce que permet de faire l’algorithme SplineBeam développé par une équipe du SHFJ en collaboration avec le CEA-List, NeuroSpin et le CHU Grenoble-Alpes.

Micelles : comment améliorer l’efficacité radiothérapeutique lorsque les tumeurs résistent ?

Wed, 23 Oct 2024 10:00:00 GMT

Des équipes du SCBM et du SHFJ, en collaboration avec le CEA-Jacob et l’ISMO ont développé une micelle perfluorée biocompatible pour améliorer l’efficacité des radiothérapies et qui serait particulièrement intéressante dans des environnements tumoraux radiorésistants.

La microfluidique en gouttelettes et l'IA pour détecter la résistance à la colistine

Mon, 30 Sep 2024 10:00:00 GMT

Une collaboration dirigée par le LERI (SPI/DMTS) a mis au point un dispositif de microfluidique en gouttes pour tester rapidement et efficacement la susceptibilité à la colistine, un antibiotique pour lequel des phénomènes de résistance bactérienne ont été observés. L’Intelligence artificielle complète la méthode pour faciliter l’étape d’analyse des images et augmenter la sensibilité du test.

L’épigénétique comme biomarqueur d’efficacité thérapeutique contre le déficit en transporteur de la créatine lié à l’X.

Tue, 17 Sep 2024 10:00:00 GMT

Des résultats obtenus par une équipe du SPI, en collaboration avec CERES Brain Therapeutics et l’Université de Sharjah (Emirats arabes unis), indique que le niveau de méthylation de l’ADN pourrait constituer un biomarqueur intéressant de l’efficacité thérapeutique d’un traitement potentiel du déficit en transporteur de la créatine lié à l’X.

PET imaging evaluation of the central effects of a drug-candidate to aid smoking cessation

Thu, 29 Aug 2024 10:00:00 GMT

A BioMaps team has used PET imaging to monitor glucose metabolism as a marker of the cerebral impact of smoking cessation, as well as the effects of a promising drug-candidate for the treatment of such cessation. By revealing the restoration of normal activity in the brain area associated with craving, these results offer hope for smoking cessation in humans

Marquage par échange isotopique : après l’hydrogène et le carbone, le soufre ?

Tue, 09 Jul 2024 10:00:00 GMT

Une équipe du SCBM met au point une méthode d’échange isotopique du soufre pour le marquage de molécules biologiquement actives. Telle une plateforme isotopique multi-échangeable, le procédé permet également un échange isotopique du carbone et d’hydrogène donnant accès à un grand nombre d’isotopologues. L’équipe met en avant le potentiel de la méthode pour vérifier l’authenticité de molécules organiques commerciales.

Nanosciences: Towards a new type of micellar phototherapy?

Wed, 12 Jun 2024 10:00:00 GMT

SCBM researchers have designed nanometric micelles that can be activated by light and constructed by self-assembly of amphiphiles derived from ferrocene, which carries a hidden therapeutic activity in the absence of activation.

Breaking a bridge and rebuilding it to radiolabel a molecule

Fri, 24 May 2024 10:00:00 GMT

Researchers at BioMaps have developed a "re-bridging agent" for the radiolabelling of biomolecules containing disulphide bridges. Their strategy has enabled several molecules of therapeutic interest to be labelled with fluorine-18, copper-64 and zirconium-89.

Nanometric micelles for targeted delivery of a prodrug against atherosclerosis

Thu, 14 Mar 2024 11:00:00 GMT

Teams from SCBM and SIMoS (DMTS) have developed nano-micelles for the vectorization of an active principle which regulates cholesterol metabolism towards atherosclerotic lesions.

Improved diagnosis of acute hepatic porphyrias using mass spectrometry

Fri, 23 Feb 2024 11:00:00 GMT

A collaborative study between SPI and a team from Hôpital Louis Mourier demonstrates the contribution of liquid chromatography coupled with mass spectrometry to the day-to-day analytical needs of a clinical laboratory. Application to the rapid quantification of biomarkers in acute hepatic porphyrias.

Functionalization of the B subunit of Shiga toxin as a vaccine tool

Fri, 26 Jan 2024 11:00:00 GMT

Researchers at SIMoS (DMTS) describe the synthesis, engineering and evaluation of the properties of the B subunit of bacterial Shiga toxin (STxB), administered mucosally, as a vaccine tool. Their results confirm the value of using a synthetic STxB in an anti-tumor and anti-infectious vaccination strategy.

Validation of a new elasticity biomarker for biological tissue diagnosis

Wed, 24 Jan 2024 11:00:00 GMT

SHFJ researchers have validated the use of a new biomarker, the nonlinear shear modulus, to measure the elasticity of biological tissues, by comparing results obtained using echography with those obtained using MRI imaging and digital simulation. This biomarker is of particular interest for the diagnosis of certain breast cancers.

Combining in silico and in vitro strategies for better therapeutic antibodies: an example with derivatives of adalimumab, an anti-TNF agent

Thu, 18 Jan 2024 11:00:00 GMT

SIMoS researchers have shown that by combining two approaches, in silico and in vitro, it is possible to select therapeutic antibodies whose functionality is preserved while reducing the risk of them inducing an undesirable immune response.

Cardiac transplantation: better graft eligibility criteria thanks to metabolomics?

Wed, 15 Nov 2023 11:00:00 GMT

In a study conducted by a team from the Marie Lannelongue Hospital, SPI researchers have established a difference between the metabolomic profiles of heart grafts harvested from pigs in a state of encephalic death or dead after controlled circulatory arrest. This work contributes to the exploration and validation of the use of hearts taken from people who have died after controlled circulatory arrest as a new source of grafts.

Click-Chemistry: optimized drug delivery from nanomicelles into tumor cells

Fri, 10 Nov 2023 11:00:00 GMT

Researchers at SCBM have used a click-and-release chemistry approach to mass-release an anti-cancer drug into cells from cleavable nanomicelles, thanks to a bioorthogonal activation process. A step towards the development of new nanomedicines

Chimie : passer par le radical anion du CO2 pour le radiomarquage de médicament est possible

Tue, 24 Oct 2023 10:00:00 GMT

Des chercheurs de l'institut montrent qu’une stratégie fondée sur la formation du radical anion CO2●- marqué au carbone 14 ou carbone 11 s’avère payante pour radiomarquer en conditions douces des médicaments.

Impact of metabolic variations on PET imaging of neuroinflammation in humans

Thu, 12 Oct 2023 10:00:00 GMT

Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation.

Radiomarquage du crizotinib au fluor-18 : un nouvel outil pour suivre par TEP la biodistribution de ce médicament

Thu, 27 Apr 2023 10:00:00 GMT

Des chercheurs du SHFJ ont mis au point la radiosynthèse au fluor-18 du crizotinib, un médicament qui ne pénètre pas dans le cerveau. Ce nouvel outil pour l’imagerie TEP permettra d’explorer de futures stratégies visant à faire passer la barrière hémato-encéphalique à ce médicament pour traiter certaines métastases cérébrales.

Combining neuroanatomical markers to strengthen the diagnosis of fetal alcohol spectrum disorder

Mon, 13 Mar 2023 11:00:00 GMT

By analyzing brain imaging data, researchers from InDEV (NeuroSpin / UMR NeuroDiderot) have identified recurrent abnormalities in subjects with fetal alcohol syndrome, the combination of which could have a particularly interesting diagnostic value for non-syndromic forms of fetal alcohol spectrum disorders.

Platinum nanoparticles to improve radiotherapy ? PET imaging provides answers

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the SHFJ laboratory at ISMO have demonstrated the value of platinum nanoparticles as potential radiosensitizing agents for radiation therapy.

Development of a new radiolabeling strategy in immunoPET for precision imaging

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the BioMaps laboratory (SHFJ) and the Molecular Engineering for Health Service (SIMoS, DMTS) developed an enzymatic approach for radiofluorination of an anti-PD-L1 Fab and compared its in vivo properties to the same Fab stochastically labeled by two conventional methods.

Glioblastoma: Does focused ultrasound increase the therapeutic efficacy of cetuximab?

Wed, 15 Feb 2023 11:00:00 GMT

Researchers from the SHFJ, in collaboration with NeuroSpin, show that the use of focused ultrasound does not increase the therapeutic effects of cetuximab on glioblastoma although the opening of the blood-brain barrier is transiently effective.

Exploring the potential of a model cyanobacterium for the photosynthetic production of high-value terpenes

Fri, 10 Feb 2023 11:00:00 GMT

Through two publications, an I2BC team demonstrates the high biotechnological potential of the model cyanobacterium Synechocystis PCC 6803 for the photosynthetic production of high value-added organic compounds, the terpenes.

From a marine toxin to a melanocortin receptor antagonist, a therapeutic target for energy metabolism disorders

Thu, 09 Feb 2023 11:00:00 GMT

A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders

Detection of monkeypox: Mass spectrometry proves once again its effectiveness

Mon, 28 Nov 2022 11:00:00 GMT

A Li2D team has released the peptidomic profile of the virus that causes monkeypox, which they established using tandem mass spectrometry. These data should help to better understand the evolution of the epidemic and allow the creation of targeted tests to potentially detect the threat more quickly and prevent a new epidemic.

Discovery of a natural peptide from black mamba venom, with anticholinergic properties

Mon, 21 Nov 2022 11:00:00 GMT

A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases.

Molecular engineering of antibodies to accommodate antigenic drift of SARS-CoV-1 and 2

Thu, 22 Sep 2022 10:00:00 GMT

Researchers from SIMoS and SPI (DMTS) demonstrate that molecular engineering of llama antibodies, capable of neutralizing SARS-CoV-1, allows to obtain optimized antibodies with very high affinities for SARS-CoV-2 and its variants, the culprits of the Covid-19 epidemic.

Dual labeling and digital imaging for the evaluation of protein-drug conjugates in preclinical models

Mon, 22 Aug 2022 10:00:00 GMT

A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs.

Fight against antibiotic resistance: two additional rapid lateral flow immuno-assays

Tue, 02 Aug 2022 10:00:00 GMT

Researchers at the LERI together with the AP-HP have developed 2 rapid and inexpensive immunological tests to detect antibiotic resistance. The novelty: the tests detect the activity of bacterial enzymes that hydrolyze extended-spectrum cephalosporins.

How to make biodrugs less immunogenic? Answer with a monoclonal antibody with anti-inflammatory properties

Mon, 20 Jun 2022 10:00:00 GMT

SIMoS team, in collaboration with Bicêtre Hospital, shows that certolizumab pegol, a pegylated monoclonal antibody fragment for anti-inflammatory use, is less likely to trigger an adverse immune response than the non-pegylated form.

Facilitating access to deuterated and tritiated molecules: towards more diversity!

Wed, 06 Apr 2022 10:00:00 GMT

Researchers from the SCBM describe a hydrogen isotope labeling process that is easy to implement and whose starting point is a "simple" mixture, in a solvent, of the product to be labeled with a pre-catalyst. Explanations of this process which finds applications in many fields including drug development or medical imaging.

Buprenorphine/benzodiazepine interaction: why is it more dangerous?

Fri, 25 Mar 2022 11:00:00 GMT

A collaboration between the SHFJ and the UMR-S 1144 (University of Paris) shows that the deleterious effect of the buprenorphine/benzodiazepine combination would result from the combined action of each drug on its target.

Deeptope: accelerating the development of therapeutic antibodies via high-throughput functional tests

Mon, 29 Nov 2021 11:00:00 GMT

Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.

Characteristics of the initial symptoms of Alzheimer's disease in young patients

Thu, 10 Jun 2021 10:00:00 GMT

Researchers from BioMaps (SHFJ) and the Department of Memory and Language Neurology (Ste Anne's Hospital) studied the early clinical signs of Alzheimer's disease (AD) reported by young patients (< 62 years old) compared to those reported in classic AD of the elderly (> 65 years old). They show that these signs are misleading and often appear in the professional context.

Evaluation of the immunogenicity of peptide-drugs containing non-natural modifications

Tue, 01 Jun 2021 10:00:00 GMT

A team from SIMoS (DMTS) in collaboration with Sanofi shows that the introduction of non-natural sequences into an immunogenic peptide attenuates the immune response against this peptide, an approach that could guide the design of less immunogenic, and therefore more effective, therapeutic peptides.

PET imaging reveals the neuropharmacology of buprenorphine

Wed, 05 May 2021 10:00:00 GMT

Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).

How works Mambalgin-1, an analgesic peptide from black mamba venom

Thu, 08 Apr 2021 10:00:00 GMT

Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.

Salmonellosis and shigellosis: a monoclonal antibody induces cross-protection

Thu, 25 Mar 2021 11:00:00 GMT

Researchers at CEA-Joliot (SPI unit in collaboration with SIMoS unit) have developed a monoclonal antibody directed against a common region of two proteins of the bacteria Shigella and Salmonella and capable of inducing cross-protection against infections caused by these bacteria.

Première étape vers un test quantitatif par spectrométrie de masse pour le diagnostic spécifique de la COVID-19 ?

Tue, 09 Mar 2021 11:00:00 GMT

Le LEMM, en collaboration avec le LI2D et l’AP-HP, développe un test de diagnostic spécifique de la Covid-19 par spectrométrie de masse qui permettrait aussi la quantification de la charge virale du patient. Objectif à terme : adapter la méthode pour la rendre plus sensible et compatible avec les équipements d’analyse des hôpitaux.

A micellar probe for fluorine magnetic resonance tumor imaging

Thu, 04 Mar 2021 11:00:00 GMT

A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.

Carbon labeling with light

Wed, 24 Feb 2021 11:00:00 GMT

Researchers from the LMC (DMTS), in collaboration with a team from AstraZeneca, have developed a labeling method, based on the exchange of carbon dioxide, simply using visible blue light and a photocatalyst.

Decompensated cirrhosis: involvement of amino acid metabolism in systemic inflammation

Mon, 14 Dec 2020 11:00:00 GMT

A European study involving CEA-Joliot provides the first overview of the amino acids circulating in the blood of patients with decompensated cirrhosis and concludes that there is a strong redistribution of their metabolism in order to provide the fuel necessary for the intense inflammatory response.

World Antimicrobial Awareness Week: the Institute continues its actions

Thu, 19 Nov 2020 11:00:00 GMT

The recent publication, in the journal Diagnostics, of a collaborative study associating AP-HP, NG-Biotech and a team from the Institute, is an opportunity to recall the Institute's commitment to the development of means of detecting antimicrobial resistance, a global phenomenon in the WHO's sights, as recalled by the World Antimicrobial Awareness Week.

Mambaquaretin: therapeutic and diagnostic interest?

Tue, 10 Nov 2020 11:00:00 GMT

In pursuing their work on mambaquaretin, SIMoS researchers conducted a collaborative study confirming the therapeutic potential of the toxin and paving the way for its use as a diagnostic tool.

Synthetic biology: new tools to increase the diversity of the 2,5-diketopiperazines produced in E.coli

Fri, 25 Sep 2020 10:00:00 GMT

Researchers from I2BC (SBIGeM), in collaboration with teams from Sorbonne University, have characterized cyclodipeptide oxidases in vivo and shown that they are valuable tools for producing dehydrogenated 2,5-diketopiperazines, precursors of bioactive molecules of pharmaceutical interest, in Escherichia coli using synthetic biology approaches.

Development of a general strategy for the isotopic labelling of carbamates by incorporation of CO2

Thu, 10 Sep 2020 10:00:00 GMT

In a study published in Chemical Communications, the Joliot Institute Carbon labeling laboratory (LMC), in collaboration with the SHFJ, provides proof of concept of a "click" strategy for carbon isotope marking of pharmaceutical molecules containing carbamates.

SARS-CoV-2 detection: mass spectrometry shows its potential for rapidity.

Thu, 06 Aug 2020 10:00:00 GMT

A team from SPI in Marcoule detected by mass spectrometry, in 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs). It thus provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.

Mapping of Ebola T-cell response: towards a new vaccine ?

Wed, 24 Jun 2020 10:00:00 GMT

SIMoS researchers, in collaboration with Genopole, Excellgene, Vaxeal holding SA (Switzerland), used a large-scale approach to map and characterize the response of CD4 T-cells from healthy donors, against two proteins from the Ebola-Zaire virus. They observed a strong response to the viral nucleoprotein (NP) and suggest that components of NP may be included in the design of new Ebola vaccines.

Salmonellosis and shigellosis: first demonstration of cross-protection induced by virulence factors SipD and IpaD

Mon, 22 Jun 2020 10:00:00 GMT

SPI researchers show for the first time, in a mouse model, the induction of cross-protection against Salmonella and Shigella infections, two pathogenic bacteria responsible for gastrointestinal diseases (typhoid, dysentery among others), one of the main causes of morbidity and mortality in several regions of Africa and Asia.

How the identification of attenuated forms of the SARS-CoV-2 virus could help to control the current epidemic ?

Tue, 12 May 2020 10:00:00 GMT

An opinion article, published in Environmental Microbiology, and written by an international consortium initiated by three researchers of Joliot Institute, proposes an original way of research on Covid-19 through the identification by sequencing of attenuated variants of the SARS-CoV-2 virus in populations at risk with little or no symptoms.

Magnetic sensors for ultra-sensitive biochips

Wed, 08 Jan 2020 11:00:00 GMT

Researchers from IRAMIS collaborated with a team from SPI (LERI) for the development of a microfluidic biochip ("lab-on-chip") based on ultra-sensitive magnetic sensors with giant magnetoresistance (GMR sensors), capable of individually and effectively detect magnetically-labeled biological targets.

A ferredoxin to fuel metabolic pathways of biotechnological interest

Mon, 14 Oct 2019 10:00:00 GMT

Researchers at BIAM and I2BC@Saclay, in collaboration with Japanese colleagues from Okayama University and Ehime, have characterized in a cyanobacterium a minor protein that diverts part of the energy from photosynthesis to secondary metabolic pathways. This discovery is promising to exploit these metabolic pathways in a biotechnological process of bioenergy production.

Lassa fever: a vaccine soon to be tested.

Wed, 09 Oct 2019 10:00:00 GMT

Researchers from Pasteur Institute, in collaboration with seven research teams, including SPI (LI2D/Marcoule), developed and evaluated the efficacy of several vaccine candidates against the virus responsible for Lassa haemorrhagic fever, endemic in Western Africa. They identified one of them as being the most effective, likely to quickly enter clinical trials in humans. Results are published in the journal Science Translational Medicine.

A new generation of nanovectors for anticancer therapies.

Wed, 12 Jun 2019 10:00:00 GMT

As part of a collaboration with MIRCen (Jacob Institute), researchers of SCBM have developed functional micellar vectors that can effectively target tumors and whose therapeutic activity is intrinsically carried by the constitutive unit of the micelle. This combination leads to better drug load and avoids premature drug release.

A promising therapeutic innovation for creatine transporter deficiency.

Fri, 17 May 2019 10:00:00 GMT

Two teams from JOLIOT (SPI / SCBM), in collaboration with the University of Cincinnati, confirm the interest of a drug candidate to treat the congenital creatine deficiency syndrome, a rare neurological childhood disease, responsible for developmental delays and intellectual disability. The results obtained in an animal model of the disease show that it is possible to administer, nasally, dodecyl creatine ester-loaded microspheres, thus improving the cognitive functions of treated animals.

« Click and Release » chemistry for the targeted delivery of drugs in vivo

Fri, 15 Mar 2019 11:00:00 GMT

A team from the SCBM, in collaboration with the SPI, the IC2MP and the University Hospital of Poitiers, has developed a bioorthogonal chemistry strategy that allows, in vivo, the controlled release of active ingredients contained in micelles-targeting cancerous tumors. These results pave the way for new strategies for targeted drug delivery.

Pain: a promising toxin isolated from a spider venom

Mon, 11 Mar 2019 11:00:00 GMT

A collaboration between SIMOPRO, Sanofi R & D, Smartox Laboratories and the Thorax Institute, has isolated a toxin with antinociceptive properties from a high-throughput electrophysiological screening of a collection of more than 100 venoms. Cyriotoxin-1a has been identified, sequenced, chemically synthesized and functionally characterized - from cell to organism in vivo.

European funding for better management of liver diseases

Fri, 01 Feb 2019 11:00:00 GMT

Europe is committed to better diagnostic and therapeutic management of patients with severe forms of cirrhosis. It finances the MICROB-PREDICT consortium, which aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis. Final goal is to uture personalized therapeutic strategies and diagnostic tools. The SPI (Joliot Institute) is the main project lead for the CEA.

Cerebral lymphoma: a new indication for [18F]Fludarabine?

Mon, 08 Oct 2018 10:00:00 GMT

A SHFJ research team (LDM-TEP, GIP Cyceron, Caen) has previously developed and produced a radiopharmaceutical, the [18F]-Fludarabine, to detect lymphomas using PET scan. The team has recently conducted a preclinical study that shows the molecule can help in diagnosis of cerebral lymphoma by differentiate it from glioblastoma, the main brain tumor. A clinical study should be launched before the end of the year.

A reliable and accessible algorithm based on EEG to diagnose states of consciousness

Fri, 05 Oct 2018 10:00:00 GMT

An international collaboration, led by the Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) and involving researchers from NeuroSpin, offers a new electroencephalogram (EEG) tool that helps the diagnosis of disorders of consciousness. Unlike other tools developed so far and dedicated to a few expert centers, “DoC-Forest” would be accessible to most of the hospitals worldwide.

Mass spectrometry for quality control of vaccines

Thu, 05 Jul 2018 10:00:00 GMT

A SPI Research Team (LI2D, Marcoule), in collaboration with CIRAD and AU-PANVAC, proposes a new quality control technique for veterinary vaccines, based on very high resolution mass spectrometry. This strategy, based on the use of an ad hoc database to measure the proportion of antigens and contaminants in the vaccine preparation, will improve the quality control of vaccines against contagious caprine pleuropneumonia.

A SIMOPRO project supported by SATT Paris-Saclay

Wed, 30 May 2018 10:00:00 GMT

A SIMOPRO project supported by SATT Paris-Saclay: in vivo validation of the efficacy of the DTR8 molecule, developed and patented at SIMOPRO (Department of Medicines and Technologies for Health) in collaboration with Inserm, as a treatment for glomerulonephritis rapidly progressive.

Toxins, vaccines, biobetters: a mission at the Butantan Institute of São Paulo

Fri, 25 May 2018 10:00:00 GMT

Last April, a delegation of experts from the DRF visited colleagues at the Butantan Institute of São Paulo, a biomedical research center that has had close links with several researchers at the Joliot Institute since 2014. This mission is is concluded by the signing of a framework agreement between the two institutes in the field of therapeutic and vaccine innovation.

An original biotechnological approach to create new bioactive molecules

Mon, 05 Mar 2018 11:00:00 GMT

Muriel Gondry's Research Team (I2BC@Saclay / SBIGeM), in collaboration with SIMOPRO and Biomolecules Laboratory of the Sorbonne University's one, produced 200 cyclodipeptides containing non-natural amino acids by luring and diverting the cellular machinery for the synthesis of proteins. This unprecedented approach significantly increases the diversity of these bioactive molecules.

Ultrasound to improve drug delivery to the brain

Mon, 19 Feb 2018 11:00:00 GMT

Researchers from NeuroSpin (Frédéric Joliot Institute/CEA) and MIRCen (François Jacob Institute/CEA Institute of Biology) have just developed an ultrasound device guided by magnetic resonance imaging (MRI) to increase temporarily and locally the vascular permeability in non-human primates, which could be used to effectively deliver drugs to the brain.

Transcription regulation by the Mediator: recent progress

Wed, 17 Jan 2018 11:00:00 GMT

Julie Soutourina (I2BC@Saclay / SBIGeM) was invited by Nature Reviews Molecular Cell Biology to publish a review on the molecular functioning of the Mediator, a multi-protein complex, conserved from yeast to humans, and essential to the regulation of the expression of genes. Potential therapeutic approaches targeting the Mediator (cancer, fungal infections) are also adressed.

Antibiotic resistance: a Joliot Institute project funded by EIT Health

Wed, 29 Nov 2017 11:00:00 GMT

A SPI/LERI Research Team has recently developed new test strips for the detection of some multi-resistant bacteria. A hospitalization project for these high-speed screening tests will be rolled out in 2018 with funding from EIT Health.

New Project Aimed at Reducing Antibiotic Resistance

Fri, 28 Apr 2017 10:00:00 GMT

The CEA Frédéric Joliot Institute is involved in project CARBAMAT to fight against antibiotic resistance. SATT Paris-Saclay, a company promoting technology transfer, supports this project.

Micellar nanovectors for tumor imaging.

Tue, 15 Dec 2015 11:00:00 GMT

In the context of a collaboration with the I²BM institute, researchers from SCBM have designed micellar vectors for targeting and visual delineation of tumors.

Modulating cerebral cholesterol: a new avenue of research to treat Alzheimer’s disease?

Mon, 14 Sep 2015 10:00:00 GMT

Two French research teams have recently shown in a rodent model that overexpression of an enzyme capable of eliminating excess cholesterol in the brain can act in a beneficial way on the tau component of the disease to completely correct it.

How does a mobile DNA sequence find its target?

Fri, 01 May 2015 10:00:00 GMT

Certain mobile DNA sequences shape genomes and are maintained over the course of generations. How is this explained? The interaction between two proteins, which is essential for their integration into a specific area of the yeast genome, has been identified. This finding has interesting implications for gene therapy.

A nano-drug for protecting neurons

Thu, 05 Mar 2015 11:00:00 GMT

A nano-drug has been developed for treating certain neurological diseases such as brain ischemia, as well as injuries to bone marrow. It is composed of a therapeutic molecule, adenosine, and the vector squalene, which allows it to circulate in the body and reach the areas to be treated.

Bio-magnet for targeted medical imaging

Fri, 20 Feb 2015 11:00:00 GMT

The CEA-IBEB has partnered with the CEA-I2BM to develop original MRI contrast agents. Nano-magnets produced by bacteria may reveal targets at the molecular level.

Towards a new generation of antiviruses

Tue, 29 Apr 2014 10:00:00 GMT

A team from the CEA-IBITECS participated in the identification of a novel role for an enzyme, the protease MMP-12, in the immune response to viral infection. The researchers developed an inhibitor of MMP-12, which enhances the immune response in a rodent model. This work, opens the way for the development of new antiviral therapies.

Parkinson’s disease: a major breakthrough thanks to gene therapy

Fri, 10 Jan 2014 11:00:00 GMT

An Anglo-French team (AP-HP, Inserm, CEA/Mircen, UPEC, Oxford Biomedica, Cambridge University) coordinated by Professor Stéphane Palfi (head of the neurosurgery department at the hôpital Henri-Mondor) conducted a gene therapy trial in 15 patients with an advanced form of Parkinson’s disease.

Quantum dot: a promising new imaging agent

Fri, 22 Mar 2013 11:00:00 GMT

The drawback to current optical imaging markers is their short life. Researchers are now developing fluorescent nanocrystals (quantum dots) to supplant these markers. A team from the CEA-iBiTec-S, in collaboration with the CEA-I2BM and ESPCI, has developed a new surface chemistry for these particularly effective nanoparticles.